BR112021016782A2 - Composto, composição, e, método para o tratamento ou prevenção de diabetes, diabetes do tipo 1, diabetes do tipo 2, tolerância à glicose comprometida, hiperglicemia e síndrome metabólica - Google Patents

Composto, composição, e, método para o tratamento ou prevenção de diabetes, diabetes do tipo 1, diabetes do tipo 2, tolerância à glicose comprometida, hiperglicemia e síndrome metabólica

Info

Publication number
BR112021016782A2
BR112021016782A2 BR112021016782A BR112021016782A BR112021016782A2 BR 112021016782 A2 BR112021016782 A2 BR 112021016782A2 BR 112021016782 A BR112021016782 A BR 112021016782A BR 112021016782 A BR112021016782 A BR 112021016782A BR 112021016782 A2 BR112021016782 A2 BR 112021016782A2
Authority
BR
Brazil
Prior art keywords
diabetes
type
composition
hyperglycemia
compound
Prior art date
Application number
BR112021016782A
Other languages
English (en)
Inventor
Carsten Behrens
Ulrich Hjørringgaard Claudia
Emiliano Cló
Hana Vánová
Henning Thøgersen
Ivan ?Najdr
Jane Spetzler
Ladislav Dro?
Werner Borchsenius MÜNZEL Martin
Milan ?Tengl
Miroslav Havránek
Per Sauerberg
Thomas Hoeg-Jensen
Thomas Kruse
Ulrich Sensfuss
Vladislav Kotek
Vojtech Bal?Ánek
Zuzana Drobnáková
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of BR112021016782A2 publication Critical patent/BR112021016782A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

composto, composição, e, método para o tratamento ou prevenção de diabetes, diabetes do tipo 1, diabetes do tipo 2, tolerância à glicose comprometida, hiperglicemia e síndrome metabólica. a presente invenção refere-se a novos derivados de insulina e seu uso no tratamento ou prevenção de condições médicas relacionadas à diabetes. os derivados de insulina são sensíveis à glicose e exibem ligação à albumina sensível à glicose. a invenção também se refere a novos intermediários. finalmente, a invenção fornece uma composição farmacêutica que compreende os derivados de insulina da invenção e o uso de tal composição no tratamento ou prevenção de condições médicas relacionadas à diabetes
BR112021016782A 2019-03-29 2020-03-27 Composto, composição, e, método para o tratamento ou prevenção de diabetes, diabetes do tipo 1, diabetes do tipo 2, tolerância à glicose comprometida, hiperglicemia e síndrome metabólica BR112021016782A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19166131 2019-03-29
EP19174671 2019-05-15
PCT/EP2020/058641 WO2020201041A2 (en) 2019-03-29 2020-03-27 Glucose sensitive insulin derivatives

Publications (1)

Publication Number Publication Date
BR112021016782A2 true BR112021016782A2 (pt) 2021-11-30

Family

ID=70189906

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021016782A BR112021016782A2 (pt) 2019-03-29 2020-03-27 Composto, composição, e, método para o tratamento ou prevenção de diabetes, diabetes do tipo 1, diabetes do tipo 2, tolerância à glicose comprometida, hiperglicemia e síndrome metabólica

Country Status (16)

Country Link
US (1) US20220184184A1 (pt)
EP (1) EP3946363A2 (pt)
JP (2) JP2022527732A (pt)
KR (1) KR102507156B1 (pt)
CN (1) CN113646329A (pt)
AU (1) AU2020255195A1 (pt)
BR (1) BR112021016782A2 (pt)
CA (1) CA3131832A1 (pt)
CL (1) CL2021002397A1 (pt)
CO (1) CO2021013251A2 (pt)
IL (1) IL285664A (pt)
MX (1) MX2021010988A (pt)
PE (1) PE20220380A1 (pt)
SG (1) SG11202108958PA (pt)
TW (2) TWI717245B (pt)
WO (1) WO2020201041A2 (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220288213A1 (en) * 2019-07-31 2022-09-15 Thermalin Inc. Insulin analogues with glucose regulated conformational switch
CA3173417A1 (en) * 2020-03-31 2021-10-07 Alborz Mahdavi Conjugates for selective responsiveness to vicinal diols
KR20230110505A (ko) * 2020-11-19 2023-07-24 프로토머 테크놀로지스 인크. 방향족 붕소-함유 화합물 및 인슐린 유사체

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR930001305B1 (ko) * 1989-10-19 1993-02-25 니뽕 유우시 가부시끼가이샤 당 응답형 고분자 복합체(Polymer Complexes of Sugar Response Type)
JP2005526009A (ja) * 2001-12-02 2005-09-02 ノボ　ノルディスク　アクティーゼルスカブ 新規グルコース依存性インスリン
EP2254905B1 (en) * 2008-03-14 2016-12-14 Novo Nordisk A/S Protease-stabilized insulin analogues
EP2448962B1 (en) * 2009-06-30 2016-10-19 Novo Nordisk A/S Insulin derivatives
US9867869B2 (en) * 2012-12-12 2018-01-16 Massachusetts Institute Of Technology Insulin derivatives for diabetes treatment
US11052133B2 (en) * 2015-05-06 2021-07-06 Protomer Technologies, Inc. Glucose responsive insulins
CA2996455A1 (en) 2015-08-25 2017-03-02 Novo Nordisk A/S Novel insulin derivatives and the medical uses hereof
CN117624207A (zh) * 2017-11-09 2024-03-01 诺和诺德股份有限公司 葡萄糖敏感性白蛋白结合衍生物
AU2019255611A1 (en) * 2018-04-16 2020-11-12 University Of Utah Research Foundation Glucose-responsive insulin

Also Published As

Publication number Publication date
TWI717245B (zh) 2021-01-21
TW202112397A (zh) 2021-04-01
JP6795718B2 (ja) 2020-12-02
PE20220380A1 (es) 2022-03-18
JP2020164525A (ja) 2020-10-08
JP2022527732A (ja) 2022-06-06
EP3946363A2 (en) 2022-02-09
WO2020201041A2 (en) 2020-10-08
IL285664A (en) 2021-10-31
TW202102253A (zh) 2021-01-16
CA3131832A1 (en) 2020-10-08
CO2021013251A2 (es) 2022-01-17
KR20210148143A (ko) 2021-12-07
CN113646329A (zh) 2021-11-12
KR102507156B1 (ko) 2023-03-09
CL2021002397A1 (es) 2022-04-22
MX2021010988A (es) 2021-10-01
WO2020201041A3 (en) 2020-11-19
AU2020255195A1 (en) 2021-10-14
US20220184184A1 (en) 2022-06-16
SG11202108958PA (en) 2021-09-29

Similar Documents

Publication Publication Date Title
BR112021016782A2 (pt) Composto, composição, e, método para o tratamento ou prevenção de diabetes, diabetes do tipo 1, diabetes do tipo 2, tolerância à glicose comprometida, hiperglicemia e síndrome metabólica
BRPI0511703B8 (pt) composto, composição farmacêutica, e, métodos de tratar diabete melito tipo 2, de retardar o início do diabete melito tipo 2, de tratar hiperglicemia, diabete ou resistência à insulina, obesidade, síndrome x, um distúrbio lipídico, aterosclerose, e uma condição
NZ592283A (en) Combination of an insulin and the GLP-1 agonist AVE0010
NO20084919L (no) Oksadiazolidindionforbindelse
BR112015010203A8 (pt) composição para a prevenção ou tratamento de diabetes, complicações diabéticas ou diabesidade, uso de um conjugado análogo da oxintomodulina, e, método para a preparação de um conjugado análogo da oxintomodulina
BR112017021311A2 (pt) composições farmacêuticas para terapia de combinação
AR047779A1 (es) Composiciones y metodos para tratar diabetes
BRPI0506791A (pt) método para imitar uma resposta à insulina de primeira fase refeição-relacionada fisiológica em diabetes do tipo 2
BRPI0519585A2 (pt) compostos de fàrmula i; processo para a fabricaÇço de compostos de fàrmula i; composiÇÕes farmacÊuticas; mÉtodo para o tratamento e/ou profilaxia de doenÇas que estço associadas com a dpp-iv e usos destes compostos
NO20053537L (no) Preparater og fremgangsmater for forebyggelse og kontroll av insulinindusert hypoglycemi.
BRPI0509573A (pt) derivados de sulfonamida-tiazolpiridina como ativadores de glicocinase úteis para o tratamento de diabetes do tipo 2
BR112015025072A2 (pt) novo derivado de ácido 3-(4-(benziloxi)fenil)hex-4-inóico, método de preparação do mesmo e composição farmacêutica para prevenção e tratamento de doenças metabólicas incluindo o mesmo como ingrediente eficaz
NO20083026L (no) Terapeutisk middel for diabetes
BR112022013009A2 (pt) Derivados de insulina, composição farmacêutica, uso do derivado da insulina e métodos para tratar ou prevenir diabetes, para aumentar a capacidade de um derivado de insulina e para aumentar a potência de um derivado de insulina
BR112013024973A2 (pt) prevenção de hipoglicemia em pacientes com diabetes mellitus do tipo 2
BR112020021245A8 (pt) Derivado de um análogo de peptídeo semelhante a glucagon 1, métodos para preparar o derivado, para prevenir e/ou tratar diabetes ou complicações diabéticas e para reduzir glicose no sangue, aumentar tolerância à glicose, reduzir apoptose de célula beta de ilhota, intensificar função de célula beta de ilhota, aumentar número de célula beta de ilhota e/ou restaurar sensibilidade à glicose de célula beta de ilhota, composição farmacêutica, usos do derivado e do análogo, análogo de peptídeo semelhante a glucagon 1, e, produto.
ECSP19083930A (es) Compuesto de insulina acilada
BR112022022885A2 (pt) Compostos de insulina acilada de ação prolongada
BR112023000270A2 (pt) Composto, composição farmacêutica, e, peptídeo
BR112014031649A2 (pt) composto representado pela fórmula 1 tendo a enzima inibidora de atividade 11b-hsd1; método para sua produção e composição farmacêutica contendo o mesmo como ingrediente ativo
BR112022022024A2 (pt) Uso de um componente (i) em combinação com um componente (ii), composição farmacêutica, medicamento composto e kit
BRPI0602397C1 (pt) composições farmacêuticas para o tratamento das doenças gordurosas do fìgado, obesidade e demais doenças associadas à sìndrome metabólica e métodos de tratamento utilizando-se as referidas composições
BR112022009510A2 (pt) Análogo de insulina, composição farmacêutica, e, método de tratamento, prevenção ou alívio de uma doença ou distúrbio ou condição
BR112022019002A2 (pt) Uso de extrato de amora para controlar a resposta glicêmica pós-prandial
BR112023001924A2 (pt) Derivados de benzimidazol, método de preparo para os mesmos e uso médico dos mesmos